Genedrive PLC
04 August 2026
4 August 2026
genedrive plc
("genedrive" or the "Company")
Genedrive® MT-RNR1 ID Kit implemented at Erasmus MC University Medical Center in the Netherlands
- Implementation at leading European hospital further expands genedrive's international adoption
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, announces that the Genedrive® MT-RNR1 ID Kit, its rapid pharmacogenetic test to prevent antibiotic-induced hearing loss ("AIHL") in newborns, has been implemented at Erasmus MC University Medical Center ("Erasmus MC") in Rotterdam, the Netherlands, effective from 3 August 2026.
Erasmus MC is one of Europe's leading university medical centres and internationally recognised for its expertise in pharmacogenetics. Its neonatal intensive care unit treats approximately 750 newborn babies each year. Implementation of the Genedrive® MT-RNR1 ID Kit is being funded by Erasmus MC's Pharmacogenetics International Expert Center, led by Professor Dr Ron H.N. van Schaik.
Dr Gino Miele, CEO of genedrive plc, said: " Erasmus MC is internationally recognised for its leadership in pharmacogenetics, and we are pleased that rapid MT-RNR1 testing is being implemented to support time-critical prescribing decisions that help protect newborn babies from profound, irreversible antibiotic-induced hearing loss.
"We continue to see growing international momentum as healthcare systems increasingly recognise the value of rapid point-of-care pharmacogenetics in improving patient outcomes and supporting more efficient healthcare delivery. This latest deployment further strengthens our presence in Europe and builds on the growing adoption of our technology in the UK and internationally"
Prof. Dr. Ron H.N. van Schaik, Full Professor Clinical Chemistry & Pharmacogenetics, Head of Department of Clinical Chemistry at Erasmus MC, said: "Aminoglycoside antibiotics remain an essential treatment for newborn babies with suspected sepsis, but a small number carry the MT-RNR1 genetic variant, placing them at risk of profound, irreversible hearing loss. Rapid MT-RNR1 testing enables us to identify those babies before treatment is given, supporting informed prescribing decisions without delaying urgently needed antibiotic treatment. We are proud to be the first medical center in the Netherlands to implement this technology into routine neonatal care."
The Genedrive® MT-RNR1 ID Kit is already in routine clinical use across more than 20 neonatal intensive care units in the UK and internationally, with clinical implementation and commercial activities progressing across Europe and the Middle East.
|
genedrive plc |
+44 (0)161 989 0245 |
|
Gino Miele: CEO / Russ Shaw: CFO |
|
|
Peel Hunt LLP (Nominated Adviser and Broker) |
+44 (0)20 7418 8900 |
|
James Steel |
|
|
5654 & Company (Media & Investor Relations) |
genedrive@5654.co.uk |
|
Matthew Neal |
+44 (0)7917 800 011 |
|
Melissa Gardiner |
+44 (0)7757 697357 |
Subscribe to our news alert service: https://investors.genedrive.com/s/efea03
About genedrive plc (http://www.genedrive.com).
genedrive plc is a UK-based, commercial-stage pharmacogenetic testing company focused on rapid, point-of-care diagnostic tests to guide safe and effective drug prescription in emergency and acute care settings.
genedrive's proprietary technology platform enables clinicians to prescribe safer and more effective therapies based on a patient's genetic profile, supporting improved outcomes while reducing pressure on healthcare systems, lowering downstream healthcare costs through the prevention of avoidable complications and earlier, more effective intervention
The Company has two CE-IVD approved and NICE-recommended tests in NHS clinical use. The Genedrive® CYP2C19 ID Kit identifies stroke patients who will not respond to the current standard of care, Clopidogrel, used to reduce risk of secondary stroke. The Genedrive® MT-RNR1 ID Kit helps prevent antibiotic-induced hearing loss (AIHL) in newborns, enabling treatment decisions within actionable timeframes at the point of care.
Headquartered in Manchester, genedrive is focused on scaling UK-developed precision diagnostics within routine care and leveraging real-world evidence to support broader international adoption and commercial growth.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.